Skip to Content

Clinuvel Pharmaceuticals Ltd ADR CLVLY

Morningstar Rating
$11.40 +0.23 (2.06%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CLVLY is trading within a range we consider fairly valued.
Price
$11.43
Fair Value
$13.62
Uncertainty
Extreme
1-Star Price
$78.85
5-Star Price
$4.14
Economic Moat
Qssh
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLVLY is a good fit for your portfolio.

Trading Information

Previous Close Price
$11.17
Day Range
$10.9611.40
52-Week Range
$8.7619.98
Bid/Ask
$10.96 / $11.59
Market Cap
$571.45 Mil
Volume/Avg
2,700 / 3,463

Key Statistics

Price/Earnings (Normalized)
21.58
Price/Sales
11.21
Dividend Yield
0.28%
Dividend Yield (Forward)
0.28%
Total Yield
0.28%

Company Profile

Clinuvel Pharmaceuticals Ltd is an Australia-based biopharmaceutical company. It is engaged in developing drugs for the treatment of genetic and vascular disorders. Its principal compound, SCENESSE is a drug for erythropoietic protoporphyria. Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to harmful UV radiation and at repigmentation of the skin due to several depigmentation disorders. Geographically, it derives a majority of its revenue from Europe and the USA.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
16

Competitors

Valuation

Metric
CLVLY
ARGX
AVH
Price/Earnings (Normalized)
21.58
Price/Book Value
5.178.824.75
Price/Sales
11.2125.516.87
Price/Cash Flow
23.79
Price/Earnings
CLVLY
ARGX
AVH

Financial Strength

Metric
CLVLY
ARGX
AVH
Quick Ratio
1.817.405.74
Current Ratio
7.448.476.25
Interest Coverage
14.05−1,243.11
Quick Ratio
CLVLY
ARGX
AVH

Profitability

Metric
CLVLY
ARGX
AVH
Return on Assets (Normalized)
22.80%−30.25%
Return on Equity (Normalized)
26.44%−35.98%
Return on Invested Capital (Normalized)
25.90%−35.49%
Return on Assets
CLVLY
ARGX
AVH

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRWyt$445.3 Bil
VRTX
Vertex Pharmaceuticals IncBklzqv$91.1 Bil
REGN
Regeneron Pharmaceuticals IncCqwslr$91.1 Bil
SGEN
Seagen Inc Ordinary SharesKqgxr$40.7 Bil
MRNA
Moderna IncLrwnk$30.7 Bil
ARGX
argenx SE ADRGlgfs$27.7 Bil
BNTX
BioNTech SE ADRHvhrn$24.1 Bil
ALNY
Alnylam Pharmaceuticals IncKztkdkl$22.0 Bil
BMRN
Biomarin Pharmaceutical IncJcgklj$17.7 Bil
INCY
Incyte CorpRnngc$12.4 Bil